Literature DB >> 33883214

Vascular Expression of Permeability-Resistant Occludin Mutant Preserves Visual Function in Diabetes.

Andreia Goncalves1, Alyssa Dreffs2, Cheng-Mao Lin2, Sarah Sheskey2, Natalie Hudson3, Jason Keil2, Matthew Campbell3, David A Antonetti2.   

Abstract

Diabetic retinopathy is one of the leading causes of vision loss and blindness. Extensive preclinical and clinical evidence exists for both vascular and neuronal pathology. However, the relationship of these changes in the neurovascular unit and impact on vision remains to be determined. Here, we investigate the role of tight junction protein occludin phosphorylation at S490 in modulating barrier properties and its impact on visual function. Conditional vascular expression of the phosphorylation-resistant Ser490 to Ala (S490A) form of occludin preserved tight junction organization and reduced vascular endothelial growth factor (VEGF)-induced permeability and edema formation after intraocular injection. In the retinas of streptozotocin-induced diabetic mice, endothelial-specific expression of the S490A form of occludin completely prevented diabetes-induced permeability to labeled dextran and inhibited leukostasis. Importantly, vascular-specific expression of the occludin mutant completely blocked the diabetes-induced decrease in visual acuity and contrast sensitivity. Together, these results reveal that occludin acts to regulate barrier properties downstream of VEGF in a phosphorylation-dependent manner and that loss of inner blood-retinal barrier integrity induced by diabetes contributes to vision loss.
© 2021 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33883214      PMCID: PMC8336002          DOI: 10.2337/db20-1220

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.337


  47 in total

Review 1.  Diabetic retinopathy.

Authors:  David A Antonetti; Ronald Klein; Thomas W Gardner
Journal:  N Engl J Med       Date:  2012-03-29       Impact factor: 91.245

2.  Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy.

Authors:  Jennifer K Sun; Adam R Glassman; Wesley T Beaulieu; Cynthia R Stockdale; Neil M Bressler; Christina Flaxel; Jeffrey G Gross; Michel Shami; Lee M Jampol
Journal:  Ophthalmology       Date:  2018-08-07       Impact factor: 12.079

3.  Plasmalemma Vesicle-Associated Protein Has a Key Role in Blood-Retinal Barrier Loss.

Authors:  Joanna Wisniewska-Kruk; Anne-Eva van der Wijk; Henk A van Veen; Theo G M F Gorgels; Ilse M C Vogels; Danielle Versteeg; Cornelis J F Van Noorden; Reinier O Schlingemann; Ingeborg Klaassen
Journal:  Am J Pathol       Date:  2016-02-12       Impact factor: 4.307

Review 4.  Occludin: one protein, many forms.

Authors:  Philip M Cummins
Journal:  Mol Cell Biol       Date:  2011-11-14       Impact factor: 4.272

5.  TGF-β signaling protects retinal neurons from programmed cell death during the development of the mammalian eye.

Authors:  Barbara M Braunger; Stefan Pielmeier; Cora Demmer; Victoria Landstorfer; Daniela Kawall; Natalie Abramov; Marco Leibinger; Ingo Kleiter; Dietmar Fischer; Herbert Jägle; Ernst R Tamm
Journal:  J Neurosci       Date:  2013-08-28       Impact factor: 6.167

6.  Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability.

Authors:  Tomoaki Murakami; Edward A Felinski; David A Antonetti
Journal:  J Biol Chem       Date:  2009-05-28       Impact factor: 5.157

7.  Identification and analysis of occludin phosphosites: a combined mass spectrometry and bioinformatics approach.

Authors:  Jeffrey M Sundstrom; Brian R Tash; Tomoaki Murakami; John M Flanagan; Maria C Bewley; Bruce A Stanley; Kristin B Gonsar; David A Antonetti
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

8.  Phosphorylation of Tyr-398 and Tyr-402 in occludin prevents its interaction with ZO-1 and destabilizes its assembly at the tight junctions.

Authors:  Bertha C Elias; Takuya Suzuki; Ankur Seth; Francesco Giorgianni; Gautam Kale; Le Shen; Jerrold R Turner; Anjaparavanda Naren; Dominic M Desiderio; Radhakrishna Rao
Journal:  J Biol Chem       Date:  2008-11-18       Impact factor: 5.157

Review 9.  Neurodegeneration in diabetic retinopathy: does it really matter?

Authors:  Rafael Simó; Alan W Stitt; Thomas W Gardner
Journal:  Diabetologia       Date:  2018-07-20       Impact factor: 10.122

10.  Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia.

Authors:  C Greene; J Kealy; M M Humphries; Y Gong; J Hou; N Hudson; L M Cassidy; R Martiniano; V Shashi; S R Hooper; G A Grant; P F Kenna; K Norris; C K Callaghan; M dN Islam; S M O'Mara; Z Najda; S G Campbell; J S Pachter; J Thomas; N M Williams; P Humphries; K C Murphy; M Campbell
Journal:  Mol Psychiatry       Date:  2017-10-10       Impact factor: 15.992

View more
  1 in total

1.  Correlation of Retinal Structure and Visual Function Assessments in Mouse Diabetes Models.

Authors:  Sarah R Sheskey; David A Antonetti; René C Rentería; Cheng-Mao Lin
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-08-02       Impact factor: 4.799

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.